-
In Case You Missed It…
Quest Media is an innovative adaptive lifestyle platform from MDA. With the power of this […]
-
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs
Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of […]
-
Disabled artists’ challenges can propel creative solutions
As an artist with Duchenne muscular dystrophy (DMD), I’ve long recognized how creativity can foster […]
-
FSHD patients sought for first clinical trial testing EPI-321
Enrollment is now ongoing in a first-in-human trial testing EPI-321, an epigenetic therapy designed to […]
-
Behind the Drug: Nusinersen (Spinraza) for SMA
Spinal muscular atrophy (SMA) is a rare genetic disease that affects the peripheral nervous system […]
-
DYNE-251 for DMD granted FDA breakthrough therapy designation
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Dyne Therapeutics’ […]
-
Dyne Therapeutics granted Breakthrough Therapy Designation for exon-51skipping therapeutic, DYNE-251
CureDuchenne was an early investor in Dyne Therapeutics in 2020, and congratulates the company for receiving Breakthrough Therapy […]
-
Dyne Therapeutics, Inc. announced today FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics has announced FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy. This […]
-
MDA Ambassador Guest Blog: Built to Rise – Strength Forged Through Every Challenge
Darlene, who was diagnosed with spinal muscular atrophy (SMA) type 3 at age 19, just […]
-
Clinical Research Alert: At-Home Research Study in People with DM1
Sanguine Biosciences, a provider of at-home clinical research services, is seeking people living with myotonic dystrophy […]
